{"entity":{"type":"insider","cik":"0001619962","url":"/insider/0001619962","json_url":"/insider/0001619962.json","name":"ROBIN SHERRINGTON","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":11,"n_filings":4,"first":"2021-06-01","last":"2024-03-08","span_basis":"filed_date"},"name_variants":[{"name":"ROBIN SHERRINGTON","source":"filing","n_filings":4,"first_seen":"2021-06-01","last_seen":"2024-03-08"}],"transactions":[{"id":3019621,"accession":"0000950170-24-028795","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0000950170-24-028795","line_url":"/filing/0000950170-24-028795","is_derivative":false,"issuer_cik":"0001582313","issuer_name":"Xenon Pharmaceuticals Inc.","issuer_ticker":"XENE","issuer_name_source":null,"issuer_url":"/issuer/0001582313","owner_cik":"0001619962","owner_name":"ROBIN SHERRINGTON","owner_display_name":"ROBIN SHERRINGTON","owner_url":"/insider/0001619962","role":"Officer (EVP, Strategy & Innovation)","role_mark":"O","role_mark_label":"Officer (EVP, Strategy & Innovation)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP, Strategy & Innovation","security_title":"Common Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7137.0,"shares_display":"7,137","price_per_share":46.2785834384195,"price_display":"46.28","price_state":"stated","total_value":330290.25,"total_display":"330,290.25","total_whole":"330,290","shares_owned_after":8398.0,"shares_owned_after_display":"8,398","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-03-07","filed_date":"2024-03-08","scope":"insider","n_lines":2},{"id":6893619,"accession":"0001209191-22-048508","txn_seq":8,"anchor":"line-8","filing_url":"/filing/0001209191-22-048508","line_url":"/filing/0001209191-22-048508","is_derivative":false,"issuer_cik":"0001582313","issuer_name":"Xenon Pharmaceuticals Inc.","issuer_ticker":"XENE","issuer_name_source":null,"issuer_url":"/issuer/0001582313","owner_cik":"0001619962","owner_name":"ROBIN SHERRINGTON","owner_display_name":"ROBIN SHERRINGTON","owner_url":"/insider/0001619962","role":"Officer (EVP, Strategy & Innovation)","role_mark":"O","role_mark_label":"Officer (EVP, Strategy & Innovation)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP, Strategy & Innovation","security_title":"Common Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":43879.0,"shares_display":"43,879","price_per_share":38.18400350965154,"price_display":"38.18","price_state":"stated","total_value":1675475.89,"total_display":"1,675,475.89","total_whole":"1,675,476","shares_owned_after":25572.0,"shares_owned_after_display":"25,572","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-09-01","filed_date":"2022-09-02","scope":"insider","n_lines":2},{"id":6893606,"accession":"0001209191-22-048508","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-22-048508","line_url":"/filing/0001209191-22-048508#line-4","is_derivative":false,"issuer_cik":"0001582313","issuer_name":"Xenon Pharmaceuticals Inc.","issuer_ticker":"XENE","issuer_name_source":null,"issuer_url":"/issuer/0001582313","owner_cik":"0001619962","owner_name":"ROBIN SHERRINGTON","owner_display_name":"ROBIN SHERRINGTON","owner_url":"/insider/0001619962","role":"Officer (EVP, Strategy & Innovation)","role_mark":"O","role_mark_label":"Officer (EVP, Strategy & Innovation)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP, Strategy & Innovation","security_title":"Common Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":21352.0,"shares_display":"21,352","price_per_share":38.57,"price_display":"38.57","price_state":"stated","total_value":823546.64,"total_display":"823,546.64","total_whole":"823,547","shares_owned_after":16796.0,"shares_owned_after_display":"16,796","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-08-31","filed_date":"2022-09-02","scope":"insider"},{"id":6607511,"accession":"0001209191-22-017318","txn_seq":7,"anchor":"line-7","filing_url":"/filing/0001209191-22-017318","line_url":"/filing/0001209191-22-017318","is_derivative":false,"issuer_cik":"0001582313","issuer_name":"Xenon Pharmaceuticals Inc.","issuer_ticker":"XENE","issuer_name_source":null,"issuer_url":"/issuer/0001582313","owner_cik":"0001619962","owner_name":"ROBIN SHERRINGTON","owner_display_name":"ROBIN SHERRINGTON","owner_url":"/insider/0001619962","role":"Officer (EVP, Strategy & Innovation)","role_mark":"O","role_mark_label":"Officer (EVP, Strategy & Innovation)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP, Strategy & Innovation","security_title":"Common Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":21710.0,"shares_display":"21,710","price_per_share":30.502422846614465,"price_display":"30.50","price_state":"stated","total_value":662207.6,"total_display":"662,207.60","total_whole":"662,208","shares_owned_after":32232.0,"shares_owned_after_display":"32,232","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-03-04","filed_date":"2022-03-08","scope":"insider","n_lines":4},{"id":5398770,"accession":"0001209191-21-036802","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001209191-21-036802","line_url":"/filing/0001209191-21-036802","is_derivative":false,"issuer_cik":"0001582313","issuer_name":"Xenon Pharmaceuticals Inc.","issuer_ticker":"XENE","issuer_name_source":null,"issuer_url":"/issuer/0001582313","owner_cik":"0001619962","owner_name":"ROBIN SHERRINGTON","owner_display_name":"ROBIN SHERRINGTON","owner_url":"/insider/0001619962","role":"Officer (EVP, Strategy & Innovation)","role_mark":"O","role_mark_label":"Officer (EVP, Strategy & Innovation)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP, Strategy & Innovation","security_title":"Common Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6067.0,"shares_display":"6,067","price_per_share":18.81,"price_display":"18.81","price_state":"stated","total_value":114120.27,"total_display":"114,120.27","total_whole":"114,120","shares_owned_after":35144.0,"shares_owned_after_display":"35,144","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-05-28","filed_date":"2021-06-01","scope":"insider","n_lines":2}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":11,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":11,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":11},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001582313","name":"Xenon Pharmaceuticals Inc.","url":"/issuer/0001582313","role":"Officer (EVP, Strategy & Innovation)","n_filings":4,"first_seen":"2021-06-01","last_seen":"2024-03-08"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001619962","retrieved_at":"2026-08-24T05:50:53+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}